For informational and research purposes only.
Research, explained. Explore peptides, supplements and hormone health with clear, practical breakdowns of what the studies actually tell us.
Metabolism, recovery and emerging research
Local reactions are common in elamipretide studies. Understand the trial counts, practical burden, formulation limits and distinction from serious hypersensitivity.
Read articleBlue color cannot establish a GHK-Cu product's identity, amount or sterility. Learn what quality tests and actual recall records can tell you.
Read articleThe HIV trials found less liver fat and a signal for slower fibrosis progression. They did not demonstrate that existing liver scarring was reversed.
Read articleIGF-1 reflects tesamorelin’s hormone effects and helps guide safety monitoring. Learn why reference ranges, clinical response, and glucose need separate attention.
Read articleVisceral-fat loss, body-weight loss and cardiovascular risk use different measurements. A closer look at tesamorelin and semaglutide trials explains the differences.
Read articleRelated kisspeptin forms share an active sequence, but their clinical evidence depends on route, exposure pattern, population and outcome.
Read articleCouple communication, sexual function and relationship quality have been studied differently. The results don't establish a general relationship treatment.
Read articleA faster pulse, stronger contraction and cardiovascular outcomes are different findings. Learn what retatrutide's trials and atrial-tissue experiments establish.
Read articleFull-length thymosin beta-4, its short fragment and modified preparations have different evidence. Learn which substance was actually tested.
Read articleHuman trials and laboratory findings explain interest in thymosin alpha-1, but cancer type, companion medicines and clinical outcomes determine relevance.
Read articleMicrodosing covers different semaglutide regimens. Separate approved titration, new observational reports and registered trials from claims they have not established.
Read articleSingle-agent trials show cagrilintide has activity of its own, while separating weight loss, glucose effects and specific safety findings.
Read article61–72 of 320 articles
